Interleukin-10: new perspectives on an old cytokine

Authors

  • David M. Mosser,

    1. Department of Cell Biology and Molecular Genetics, The Maryland Pathogen Research Institute, University of Maryland, College Park, MD, USA.
    Search for more papers by this author
  • Xia Zhang

    1. Department of Cell Biology and Molecular Genetics, The Maryland Pathogen Research Institute, University of Maryland, College Park, MD, USA.
    Search for more papers by this author


David M. Mosser
Department of Cell Biology and Molecular Genetics
The Maryland Pathogen Research Institute
University of Maryland
3102 Bioscience Research Building
College Park, MD 20742, USA
Tel.: +1301 314 2594
Fax: +1301 314 1248
e-mail: dmosser@umd.edu

Abstract

Summary: Interleukin-10 (IL-10) has long been recognized to have potent and broad-spectrum anti-inflammatory activity, which has been unequivocally established in various models of infection, inflammation, and even in cancer. However, because of the marginal successes of the initial clinical trials using recombinant IL-10, some of the interest in this cytokine as an anti-inflammatory therapeutic has diminished. New work showing IL-10 production from regulatory T cells and even T-helper 1 T cells has reinvigorated the field and revealed the power of this cytokine to influence immune responses. Furthermore, new preclinical studies suggest that combination therapies, using antibodies to IL-10 along with chemotherapy, can be effective in treating bacterial, viral, or neoplastic diseases. Studies to understand IL-10 gene expression in the various cell types may lead to new therapeutics to enhance or inhibit IL-10 production. In this review, we summarize what is known about the regulation of IL-10 gene expression by various immune cells. We speculate on the promise that this cytokine holds to influence immune responses and mitigate immune pathologies.

Ancillary